Shares of Fortress Biotech Inc. (FBIO) are up over 3% at $4.40 in premarket trading on Tuesday, as its subsidiary Cyprium Therapeutics approaches a key FDA decision.CUTX-101, a subcutaneous injectable formulation of copper histidinate, developed by Cyprium and proposed for the treatment of Menkes disease, is awaiting a decision from the FDA, expected by January 14, 2025. This is the therapy's second go-around with the FDA.Last October, the U.S. regulatory agency declined to approve CUTX-101, citing observa ...